.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A02B_DrugsForPepticUlcerAndGastroOesophagealRefluxDis.A02BA03_Famotidine.Famotidine .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A02B_DrugsForPepticUlcerAndGastroOesophagealRefluxDis.A02BA03_Famotidine.Famotidine| name: | Famotidine |
| ATC code: | A02BA03 | route: | oral |
| n-compartments | 1 |
Famotidine is a histamine H2 receptor antagonist used to reduce stomach acid production. It is commonly indicated for the treatment of peptic ulcer disease, gastroesophageal reflux disease (GERD), and conditions that cause excessive stomach acid such as Zollinger-Ellison syndrome. Famotidine is approved and widely used today both as a prescription and over-the-counter medication.
Pharmacokinetic parameters in healthy adult volunteers after a single 40 mg oral dose.
McCann, S, et al., & Gonzalez, D (2023). Population Pharmacokinetics of Posaconazole in Immune-Compromised Children and Assessment of Target Attainment in Invasive Fungal Disease. Clinical pharmacokinetics 62(7) 997–1009. DOI:10.1007/s40262-023-01254-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37179512
Avner, DL (2000). Clinical experience with pantoprazole in gastroesophageal reflux disease. Clinical therapeutics 22(10) 1169–1150. DOI:10.1016/s0149-2918(00)83061-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11110229
Shaefer, MS, et al., & Stratta, RJ (1995). Evaluation of the pharmacokinetic interaction between cimetidine or famotidine and cyclosporine in healthy men. The Annals of pharmacotherapy 29(11) 1088–1091. DOI:10.1177/106002809502901102 PUBMED:https://pubmed.ncbi.nlm.nih.gov/8573949